Nobivac® Lepto4

 Leptospira Canicola, Grippotyphosa, Icterohaemorrhagiae, Pomona Bacterin

The first and only canine vaccine specifically indicated to protect against disease and mortality and leptospiruria (urinary shedding).

Features and benefits

  • Prevented mortality caused by 4 virulent Leptospira serovars1
  • Prevents liver dysfunction and thrombocytopenia1
  • The only vaccine indicated to protect against mortality and leptospiruria
  • Significantly reduced leptospiremia1
  • Proven safe and well tolerated in multiple studies1
  • Available in both a monovalent and combination formulation (DAPPv)


  • Indicated to aid in the prevention of disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa
  • Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae
  • Aids in the prevention of leptospiruria associated with L. pomona
  • Recommended for use in healthy dogs 8 weeks of age or older

Safety information

  • Safety confirmed in a 749-dog field study1
  • Well tolerated on subcutaneous administration
  • Proven safe across a variety of breeds and ages
  • Now featuring an even higher level of quality due to the VacciPure™ filtration

Administration and Dosage

  • Subcutaneous injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Last dose may be given at 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


1. Data on file, Merck Animal Health.